Eli Lilly And Co vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Eli Lilly And Co trades at $1,216.77 (market cap $1.08T), while Direxion Daily TSLA Bull 2X Shares trades at $7.87. The key difference: Eli Lilly And Co pays a 0.57% dividend while Direxion Daily TSLA Bull 2X Shares pays none. Which is the better fit depends on your goals.
| LLY | TSLL | |
|---|---|---|
Market Cap | $1.08T | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.24K | $23.03 |
52-Week Low | $639.43 | $6.74 |
Enterprise Value | $1.13T | — |
Dividend Yield | 0.57% | — |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
TSLL (Direxion Daily TSLA Bull 2X Shares ETF) trades at $8.15, down 0.73% on the day, with technical indicators showing a bearish trend. The ETF, which aims to deliver twice Tesla's daily returns, faces challenges as recent news highlights volatility risks for leveraged Tesla investments. Key support sits at $8 with resistance at $9, while RSI levels suggest mixed momentum signals.
The outlook remains cautious given the bearish technical signals and leveraged structure amplifying Tesla's volatility. Investment opportunities exist for short-term traders betting on Tesla rebounds, but risks include magnified losses during downturns and the structural decay of daily reset leveraged ETFs in volatile markets.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →